
A staffer shows off Peko-chan no Hoppe Premium cakes jointly developed by Kintetsu Department Store Co. and Fujiya Co.
21:00 JST, November 12, 2023
Kintetsu Department Store Co. and major confectionery maker Fujiya Co. have jointly opened Pekolicious, a store selling newly developed sweets by Fujiya, at the department store’s flagship location in the Abeno Harukas complex in Abeno Ward, Osaka.
Among products available at the store are Peko-chan no Hoppe Premium cakes, a new product based on Peko-chan no Hoppe, a cream sponge cake launched by the company in 1994. Peko-chan no Hoppe Premium cakes each cost around ¥200-¥300.
The new products are freshly made in-store by squeezing specially made cream onto fluffy sponge cake. “Milky and custard,” almond chocolate and four other flavors are available, including the seasonally limited flavor of Mont Blanc.
Baked cookies in cans also can be purchased. “We hope customers will enjoy the sweets not only as gifts but also as a treat for themselves,” an official of the department store said.
Kintetsu Department Store strengthens its business by not just seeking tenants, but also drawing up franchise contracts with businesses and running them. In the case of Pekolicious, the department store and Fujiya worked together on elements such as store design, in addition to the products.
Top Articles in Features
-
Japanese Students Use Traditional Pickle to Create Novel Wagashi Confectionery
-
My Spendthrift Mother Constantly Asks Me for Money
-
Kawazu Cherry Blossoms in Full Bloom in Japan’s Shizuoka Pref.; Festival to Be Held through March 8
-
Tourists Ignore Safety Barriers Near Famous Zao ‘Snow Monsters’ in Japan
-
Tottori: 95-Year-Old Japanese Descendent from Philippines Visits Father’s Grave
JN ACCESS RANKING
-
Producer Behind Pop Group XG Arrested for Cocaine Possession
-
Japan PM Takaichi’s Cabinet Resigns en Masse
-
Man Infected with Measles Reportedly Dined at Restaurant in Tokyo Station
-
Japan Figure Skating Legend Yuzuru Hanyu Is Proud Disaster Survivor and Gold Medalist, Vows to Continue Support Efforts
-
iPS Treatments Pass Key Milestone, but Broader Applications Far from Guaranteed

